Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
The British Journal of Psychiatry. Supplement|April 2, 2004
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medicationsPatrizia Cavazzoni, Nitai Mukhopadhyay, Christopher Carlson, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 26, 2003
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trialPatrizia Cavazzoni, Yoko Tanaka, Suraja M Roychowdhury, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 17, 2005
Diabetes mellitus and antipsychotic treatment in the United KingdomChristopher Carlson, Kenneth Hornbuckle, Frank DeLisle, et al.Journal of Clinical Psychopharmacology|July 21, 2006
Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychoticsThomas A Hardy, Eva Marquez, Ludmila Kryzhanovskaya, et al.Journal of Clinical Epidemiology|March 26, 2003
A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United StatesJohn B Buse, Patrizia Cavazzoni, Kenneth Hornbuckle, et al.The Journal of Clinical Psychiatry|January 14, 2003
A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatmentAnne Duffy, Martin Alda, Stan Kutcher, et al.The Journal of Clinical Psychiatry|November 6, 2002
Is response to prophylactic lithium a familial trait?Paul Grof, Anne Duffy, Patrizia Cavazzoni, et al.The Journal of Clinical Endocrinology and Metabolism|June 7, 2002
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placeboMargaret O Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, et al.Clinical Therapeutics|July 25, 2006
A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjectsMalcolm Mitchell, Robert Riesenberg, Mohammad A Bari, et al.The Journal of Clinical Endocrinology and Metabolism|December 13, 2003
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clampMargaret Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, et al.Pageof 2